Project Grant R01HL180379
Award Date 8/15/25
Completion Date 5/31/29
Dollars Obligated $740K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
- This federal Project Grant award, valued at $695,997.00 and awarded on Aug 18, 2025, supports research conducted by Mayo Clinic Arizona under the Cardiovascular Diseases Research program (CFDA 93.837) administered by the National Heart, Lung, and Blood Institute. The research aims to investigate the role of the Programmed Cell Death 4 (PDCD4) gene in mitigating doxorubicin-induced cardiotoxicity, a common side effect of anthracycline chemotherapy drugs. The project utilizes a juvenile mouse...
- This federal Project Grant award of $680,583.00 from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research to discover genetic modifiers and novel therapies for anthracycline-induced cardiotoxicity. The study aims to use zebrafish models to test candidate genes identified from human genome-wide association studies, as well as explore the role of aging-associated epicardial remodeling in cardiotoxicity. Key areas of focus include...
- The U.S. National Heart, Lung, and Blood Institute awarded a $803,768 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the J. David Gladstone Institutes, a non-profit biomedical research organization in California. The grant funding supports a research project titled "Chromatin Regulation of Immune Cells in Myocardial Inflammation", which aims to elucidate the role of the epigenetic regulator BRD4 in controlling monocyte differentiation and macrophage...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $165,672 to New York University School of Medicine to conduct research aimed at increasing heart transplant (HT) volume in the United States. The key objectives are to: Investigate the impact of donor risk factors, such as coronary artery disease, left ventricular dysfunction, and older age, on post-HT outcomes using European and U.S. registry data. This...
- This $229,608 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research investigating the role of pleural mesothelial cells in lung injury, repair, and regeneration. The award to Mayo Clinic aims to conduct lineage-tracing experiments in mouse models of lung injury and regeneration, and subsequent genomic analysis of the collected pleural mesothelial cells. This research seeks to improve the understanding of repair...
- This Project Grant award, valued at $1,088,500.00, was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The University of Iowa. The award supports three independent research projects related to genetic and molecular mechanisms of heart disease. Project #1 aims to define microRNA (miR) targeting events and their biological relevance in the heart, as well as understand the clinical significance of single nucleotide polymorphisms (SNPs)...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $811,885 in funding to the J. David Gladstone Institutes in California to conduct research on epigenomic mechanisms of cardiac fibrosis and heart failure. The project aims to investigate the role of the MEOX1 gene as a key transcriptional regulator of fibroblast activation, fibrosis, and heart failure pathogenesis. The research leverages novel genetic mouse...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
- This federal Project Grant award of $193,984 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the interplay between inflammation, angiogenesis, myocardial perfusion, and myocardial function in patients with advanced chronic kidney disease (CKD). The project, conducted by Brigham & Women's Hospital Inc., aims to mechanistically explore cardiovascular health before and after kidney transplantation. Key objectives...
- The National Heart, Lung, and Blood Institute awarded a $160,092 project grant to Mayo Clinic Arizona under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a longitudinal study evaluating sleep health, sleep disorders, and cognitive functioning in heart transplant recipients. The study will enroll 30 adult heart transplant recipients and collect repeated measures at 6, 9, and 12 months post-transplant to: 1) describe sleep health characteristics, sleep disorders, and...